Abstract
A Phase 1b Study of Blinatumomab Including Subcutaneous Administration in Relapsed / Refractory (R/R) Indolent Non Hodgkin's Lymphoma (NHL)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have